# Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for the Treatment of Metastatic/Recurrent Advanced Solid Tumors

> **NCT05430360** · PHASE1 · TERMINATED · sponsor: **Grit Biotechnology** · enrollment: 2 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **BIOLOGICAL:** GT201

## Key facts

- **NCT ID:** NCT05430360
- **Lead sponsor:** Grit Biotechnology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-01-04
- **Primary completion:** 2025-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** The study was terminated from a business perspective.
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05430360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05430360, "Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for the Treatment of Metastatic/Recurrent Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05430360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*